Showing 3001-3010 of 5646 results for "".
- EyePoint Pharmaceuticals Announces Positive Topline Data from the Phase 2 DAVIO 2 Trial of EYP-1901 in Wet AMDhttps://modernod.com/news/eyepoint-pharmaceuticals-announces-positive-topline-data-from-the-phase-2-davio-2-trial-of-eyp-1901-in-wet-amd/2481990/In a phase 2 study, EyePoint Pharmaceuticals’ wet AMD drug candidate demonstrated noninferiority to Eylea—with a less frequent dosing regimen. EyePoint leadership said the sustained-release implant could represent a 'paradigm-altering maintenance treatment' for patients with w
- OliX Pharmaceuticals Announces Safety Data and Preliminary Efficacy Effects in a Phase 1 Trial of OLX10212 for AMDhttps://modernod.com/news/olix-pharmaceuticals-announces-positive-safety-data-and-preliminary-efficacy-effects-in-a-phase-1-trial-of-olx10212-for-age-related-macular-degeneration/2481988/OliX Pharmaceuticals announced positive results from a phase 1 study evaluating the safety and tolerability of OLX10212 for the treatment of age-related macular degeneration (AMD). The development of small interfering RNAs (siRNAs), like OLX10212, which showed efficacy in nonclinical models
- RetinAI Joins Ryan Initiative for Macular Research AMD Consortiumhttps://modernod.com/news/retinai-joins-ryan-initiative-for-macular-research-amd-consortium/2481987/RetinAI Medical announced that they are now joining the Ryan Initiative for Macular Research (RIMR) Age-related Macular Degeneration (AMD) Imaging Consortium, a non-profit group of physicians, researchers, and industry partners working together to define optimal biomarkers and endpoints in AMD.</
- Oxurion to File for Bankruptcy After Failed DME Trialhttps://modernod.com/news/oxurion-to-file-for-bankruptcy-after-failed-dme-trial/2481978/Oxurion said it has decided to file for bankruptcy after announcing topline data from its KALAHARI phase 2, Part B trial for diabetic macular edema (DME). The trial did not demonstrate that its novel PKal inhibitor, THR-149, improved vision as much as the comparator,
- Mass Eye and Ear Researchers Develop Potential Glaucoma Treatment Strategy to Guide Stem Cells to the Retinahttps://modernod.com/news/mass-eye-and-ear-researchers-develop-potential-glaucoma-treatment-strategy-to-guide-stem-cells-to-the-retina/2481977/A multidisciplinary team led by researchers at the Schepens Eye Research Institute of Mass Eye and Ear has identified a promising new strategy for glaucoma cell replacement therapy. In a new study, researchers changed the microenvironment in the eye in a way that enabled them to take st
- OIG Publishes General Compliance Program Guidance for the Health Care Industryhttps://modernod.com/news/oig-publishes-general-compliance-program-guidance-for-the-health-care-industry/2481964/According to an advisory from law firm Arnold & Porter, on November 6, the Department of Health and Human Services Office of Inspector General (OIG) released a
- Alcon Canada Launches Clareon Vivity, its Latest Advancement in Presbyopia Correcting IOLshttps://modernod.com/news/alcon-canada-launches-clareon-vivity-its-latest-advancement-in-presbyopia-correcting-iols/2481956/Alcon announced that Clareon Vivity, the first and only non-diffractive extended depth of focus (EDOF) IOL on Alcon’s lens platform, is now available in Canada. [1-6] Clareon Vivity is designed to provide high-quality vision from distance to functional near with a visual dist
- ASCRS Names Abigail Markward New Executive Directorhttps://modernod.com/news/ascrs-names-abigail-markward-new-executive-director/2481952/The American Society of Cataract and Refractive Surgery (ASCRS) has named Abigail Markward as the new Executive Director of the ASCRS Foundation. Ms. Markward has more than two decades of expertise in strategic communications, marketing, publishing, and nonprofit roles. Most recent
- Ace Vision Group Adds Four Ophthalmologists to Medical Advisory Board; Launches New Corporate and Medical Affairs Websiteshttps://modernod.com/news/ace-vision-group-adds-four-ophthalmologists-to-medical-advisory-board-launches-new-corporate-and-medical-affairs-websites/2481941/Ace Vision Group announced the addition of Cathleen McCabe, MD; James Katz, MD; Ehsan Sadri, MD; and Dagny Zhu, MD, to its medical advisory board. These prominent ophthalmologists will contribute expertise to advance the development and implementation of novel solutions for e
- Vision Innovation Partners Names Chris Moore as CEOhttps://modernod.com/news/vision-innovation-partners-names-chris-moore-as-ceo/2481914/Vision Innovation Partners (VIP), a Mid-Atlantic eye care platform with nearly 70 locations, announced the promotion of existing board member and current President, Chris Moore, to Chief Executive Officer. Former CEO and founder Mike Dunn is now serving as Executive Vice President of Business Dev